FILING ANALYSIS · THURSDAY, NOVEMBER 5
Aclaris Therapeutics, Inc. ACRS — 8-K: Results of Operations and Financial Condition
neutral
Aclaris Therapeutics reported positive primary analysis results from Phase 1b proof-of-concept trials of ATI-052 in atopic dermatitis and asthma, and expects to initiate a Phase 2b trial of modzatinib in lichen planus in the fourth quarter of 2026, but no quantified surprise was disclosed in terms of earnings or guidance beats.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →